Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Dodel

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
The Lancet. Neurology|July 10, 2003
Immunotherapy for Alzheimer's diseaseRichard C Dodel, Harald Hampel, Yansheng Du
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 16, 2004
Systematic assessment of decision models in Parkinson's diseaseUwe Siebert, Bernhard Bornschein, Tobias Walbert, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Health-related quality of life and economic burden in patients with restless legs syndromeJens P Reese, Karin Stiasny-Kolster, Wolfgang H Oertel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2003
Role of dopamine transporter SPECT for the practitioner and the general neurologistWolfgang H Oertel, Anja Gerstner, Helmut Höffken, et al.
Neuroscience Letters|May 3, 2006
Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's diseaseCandan Depboylu, Frank Lohmüller, Yansheng Du, et al.
Dementia and Geriatric Cognitive Disorders|January 24, 2004
An interleukin-6 promoter variant is not associated with an increased risk for Alzheimer's diseaseCandan Depboylu, Frank Lohmüller, Petra Gocke, et al.
Journal of Parkinson'S Disease|August 14, 2013
The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in miceVanessa Stuckenholz, Michael Bacher, Monika Balzer-Geldsetzer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2003
Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approachRichard C Dodel, Helmut Höffken, J Carsten Möller, et al.
Neuroscience Letters|April 8, 2019
Effect of naturally occurring α-synuclein-antibodies on toxic α-synuclein-fragmentsMonika Rabenstein, Daniela Besong Agbo, Elias Wolf, et al.
Dementia and Geriatric Cognitive Disorders|November 30, 2011
Association of clusterin gene polymorphisms with late-onset Alzheimer's diseaseHuiying Gu, Xing Wei, Shirley Chen, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The Lancet. Neurology|July 10, 2003
Immunotherapy for Alzheimer's diseaseRichard C Dodel, Harald Hampel, Yansheng Du
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 16, 2004
Systematic assessment of decision models in Parkinson's diseaseUwe Siebert, Bernhard Bornschein, Tobias Walbert, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Health-related quality of life and economic burden in patients with restless legs syndromeJens P Reese, Karin Stiasny-Kolster, Wolfgang H Oertel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2003
Role of dopamine transporter SPECT for the practitioner and the general neurologistWolfgang H Oertel, Anja Gerstner, Helmut Höffken, et al.
Neuroscience Letters|May 3, 2006
Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's diseaseCandan Depboylu, Frank Lohmüller, Yansheng Du, et al.
Dementia and Geriatric Cognitive Disorders|January 24, 2004
An interleukin-6 promoter variant is not associated with an increased risk for Alzheimer's diseaseCandan Depboylu, Frank Lohmüller, Petra Gocke, et al.
Journal of Parkinson'S Disease|August 14, 2013
The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in miceVanessa Stuckenholz, Michael Bacher, Monika Balzer-Geldsetzer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2003
Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approachRichard C Dodel, Helmut Höffken, J Carsten Möller, et al.
Neuroscience Letters|April 8, 2019
Effect of naturally occurring α-synuclein-antibodies on toxic α-synuclein-fragmentsMonika Rabenstein, Daniela Besong Agbo, Elias Wolf, et al.
Dementia and Geriatric Cognitive Disorders|November 30, 2011
Association of clusterin gene polymorphisms with late-onset Alzheimer's diseaseHuiying Gu, Xing Wei, Shirley Chen, et al.
Pageof 2